Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Diabetic Medicine

• Publication date

  2004-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-5491.2004.01258.xPMID 15270789
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Addition of rosiglitazone to metformin is most effective in obese, insulin‐resistant patients with type 2 diabetes

  2003cited by this paper
• A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus.

  2003cited by this paper
• Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.

  2003cited by this paper
• Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.

  2003cited by this paper
• Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes.

  2003cited by this paper
• Quantitative insulin sensitivity check index and the reciprocal index of homeostasis model assessment in normal range weight and moderately obese type 2 diabetic patients.

  2003cited by this paper
• Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.

  2002cited by this paper
• Pioglitazone reduces atherogenic dense low density lipoprotein (LDL) particles in patients with type 2 diabetes mellitus

  2002cited by this paper
• Nonalcoholic fatty liver disease.

  2002cited by this paper
• Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.

  2002cited by this paper
• Approach to lipoprotein management in 2001 National Cholesterol Guidelines.

  2002cited by this paper
• Peroxisome proliferator-activated receptor agonists, hyperlipidaemia, and atherosclerosis.

  2002cited by this paper
• Total cholesterol/HDL cholesterol ratio vs LDL cholesterol/HDL cholesterol ratio as indices of ischemic heart disease risk in men: the Quebec Cardiovascular Study.

  2001cited by this paper
• Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.

  2001cited by this paper
• Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.

  2001cited by this paper
• The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

  2001cited by this paper
• The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)).

  2001cited by this paper
• Insulin sensitivity and its measurement: structural commonalities among the methods.

  2000cited by this paper
• Combining sulfonylureas and other oral agents.

  2000cited by this paper
• Non-alcoholic steatohepatitis: association with obesity and insulin resistance, and influence of weight loss.

  2000cited by this paper
• Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: studies in subjects with various degrees of glucose tolerance and insulin sensitivity.

  2000cited by this paper
• Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

  2000cited by this paper
• Frequency of liver disease in type 2 diabetic patients treated with oral antidiabetic agents.

  1999cited by this paper
• Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

  1998cited by this paper
• Changes in Amylin and Amylin-Like Peptide Concentrations ana (β-Cell Function in Response to Sulfonylurea or Insulin Therapy in NIDDM

  1998cited by this paper
• Troglitazone in Combination With Sulfonylurea Restores Glycemic Control in Patients With Type 2 Diabetes

  1998cited by this paper
• Correct Homeostasis Model Assessment (HOMA) Evaluation Uses the Computer Program

  1998cited by this paper
• How good a marker is insulin level for insulin resistance?

  1993cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris Prospective Study, 15-year follow-up

  1991cited by this paper
• Nonalcoholic fatty liver disease.

  1986cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

  1972cited by this paper
• The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2000 by The Endocrine Society Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans

  year unknowncited by this paper

• Factors Affecting the Treatment Heterogeneity of PPARγ and Pan-PPAR Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Machine Learning-Based Meta-Regression Analysis

  2026cites this paper
• Management of dyslipidaemia in patients with comorbidities: facing the challenge: type 2 diabetes mellitus

  2025cites this paper
• Preparation and in-vitro, in-vivo characterisation of pioglitazone loaded chitosan/PEG blended PLGA biocompatible nanoparticles

  2022cites this paper
• Levels of Myeloperoxidase, Malondialdehyde and Lipid Profile in Type 2 Diabetic Patients on Metformin Versus Glibenclamide Therapy

  2021cites this paper
• Synthesis of a novel glibenclamide-pioglitazone hybrid compound and its effects on glucose homeostasis in normal and insulin-resistant rats.

  2021cites this paper
• Electroacupuncture combined with acarbose improves insulin sensitivity via peroxisome proliferator–activated receptor γ activation and produces a stronger glucose-lowering effect than acarbose alone in a rat model of steroid-induced insulin resistance

  2020cites this paper
• Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future

  2018cites this paper
• Favorable cardiovascular effects of pioglitazone: a meta-analysis

  2017cites this paper
• Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline Update From the American College of Physicians.

  2017cites this paper
• Addition of dipeptidyl peptidase-4 inhibitors to sulphonylureas and risk of hypoglycaemia: systematic review and meta-analysis

  2016cites this paper
• Syddansk Universitet Endocrine and metabolic characteristics in polycystic ovary syndrome

  2016influential citation
• Insulin resistance Hyperinsulinemia Ovarian and adrenal dysfunction Testosterone Abdominal obesity Inflammation Inheritance Unknown factors Diabetes

  2016influential citation
• Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

  2015cites this paper
• WITHDRAWN: Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.

  2015cites this paper
• Anti-diabetic effect of Capparis spinosa L. root extract in diabetic rats

  2015cites this paper
• Pioglitazone hydrochloride: chemopreventive potential and development of site-specific drug delivery systems

  2015cites this paper
• Cardiovascular safety of sulfonylureas: a meta‐analysis of randomized clinical trials

  2013cites this paper
• Do thiazolidinediones still have a role in treatment of type 2 diabetes mellitus?

  2013cites this paper
• A Factorial study on the formulation and evaluation of Pioglitazonecontrolled release Matrix Tablets

  2013cites this paper
• SERUM ELECTROLYTES CHANGES WITH ATHEROGENIC INDEX OF PLASMA IN HYPOTHYROID DIABETIC (TYPE-2) YOUNG MALES

  2013cites this paper
• A COMPARATIVE EVALUATION OF ETHYL CELLULOSE AND ETHYLENE VINYL ACETATE MICROCAPSULES OF PIOGLITAZONE FOR CONTROLLED RELEASE Research Article

  2012cites this paper
• Table of Contents AHRQ ’ s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes : A Summary of the Key Findings

  2012cites this paper
• High fasting serum glucose in non-diabetic subjects ≥45 years is an indicator of future cardiovascular events as it is positively associated with atherogenic index of plasma

  2012cites this paper
• Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus: A Clinical Practice Guideline From the American College of Physicians

  2012cites this paper
• AHRQ’s Comparative Effectiveness Research on Oral Medications for Type 2 Diabetes: A Summary of the Key Findings

  2012cites this paper
• Nuclear receptor control of opposing macrophage phenotypes in cardiovascular disease.

  2012cites this paper
• Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)

  2012cites this paper
• Pioglitazone

  2012cites this paper
• Uterine Growth Retardation, Life Style, Genetic Susceptibility, Prevention and Treatment

  2011influential citation
• An XML Based Framework for Merging Incomplete and Inconsistent Statistical Information from Clinical Trials

  2010cites this paper
• Thiazolinedione treatment in PCOS – an update

  2010cites this paper
• Efficacy and Tolerability of Pioglitazone in Patients with Type 2 Diabetes Mellitus

  2010cites this paper
• Abstracts of the 19th Annual Meeting and Clinical Congress of the American Association of Clinical Endocrinologists. April 21-25, 2010. Boston, Massachusetts, USA.

  2010cites this paper
• Blutzucker-Senkung und kardiovaskulärer Vorteil: Was wissen wir heute?

  2010cites this paper
• Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ 2

  2009cites this paper
• Durable glycaemia — the promised land

  2009cites this paper
• Rede fi ning the role of thiazolidinediones in the management of type 2 diabetes

  2009cites this paper
• Redefining the role of thiazolidinediones in the management of type 2 diabetes

  2009cites this paper
• Risk management in the treatment of type 2 diabetes with pioglitazone

  2009cites this paper
• The backbone of oral glucose‐lowering therapy: time for a paradigm shift?

  2009cites this paper
• Combined Pioglitazone and Metformin Treatment Maintains the Beneficial Effect of Short-Term Insulin Infusion in Patients with Type 2 Diabetes: Results from a Pilot Study

  2009cites this paper
• Medikamentöse antihyperglykämische Therapie des Diabetes mellitus Typ2 Update der Evidenzbasierten Leitlinie der Deutschen Diabetes-Gesellschaft Pharmacological Antihyperglycemic Therapy of Type2 Diabetes mellitus Update of the Evidence-Based Guidelines of the German Diabetes Association

  2009cites this paper
• Design and in vitro Evaluation of Mucoadhesive Microcapsules of Pioglitazone

  2009cites this paper
• Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus*

  2009cites this paper
• Review: Durable glycaemia — the promised land:

  2009cites this paper
• Performing meta-analysis with incomplete statistical information in clinical trials

  2008cites this paper
• Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis.

  2008cites this paper
• Drug Class Review: Thiazolidinediones: Final Report Update 1

  2008cites this paper
• Pioglitazone and cardiovascular risk. A comprehensive meta‐analysis of randomized clinical trials

  2008cites this paper
• Hepatic dysfunction and insulin insensitivity in type 2 diabetes mellitus: a critical target for insulin‐sensitizing agents

  2008cites this paper
• The cardiovascular effects of the thiazolidinediones: a review of the clinical data.

  2007cites this paper
• Pioglitazone in the management of Type 2 diabetes and beyond

  2007cites this paper
• PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study

  2007cites this paper
• Rosiglitazone reduces office and diastolic ambulatory blood pressure following 1‐year treatment in non‐diabetic subjects with insulin resistance

  2007cites this paper
• Effect of pioglitazone on the drivers of cardiovascular risk in type 2 diabetes

  2007cites this paper
• Insulin, other hypoglycemic drugs, and glucagon

  2007cites this paper
• [Effects of thiazolidinediones on dyslipidemia in patients with type 2 diabetes. Are all equally vasoprotective?].

  2007cites this paper
• Pioglitazone plus glimepiride: a promising alternative in metabolic control

  2007cites this paper
• A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

  2007cites this paper
• Effects of pioglitazone on lipid and lipoprotein metabolism

  2007cites this paper
• Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non‐diabetic patients with coronary artery disease

  2007cites this paper
• Thiazolidinediones and the risk of edema: a meta-analysis.

  2007cites this paper
• Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes

  2007cites this paper
• Coronary artery disease in women: a review on prevention, pathophysiology, diagnosis, and treatment

  2006cites this paper
• Metformin and pioglitazone: effectively treating insulin resistance

  2006cites this paper
• Effect of pioglitazone on glucose metabolism and luteinizing hormone secretion in women with polycystic ovary syndrome.

  2006cites this paper
• A Meta‐Analysis of the Effect of Thiazolidinediones on Blood Pressure

  2006cites this paper
• Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.

  2006cites this paper
• Pioglitazone: an antidiabetic drug with cardiovascular therapeutic effects

  2006cites this paper
• Pioglitazone for type 2 diabetes mellitus.

  2006cites this paper
• Impact of thiazolidenediones on serum lipoprotein levels

  2006cites this paper
• Pioglitazone: an antidiabetic drug with the potency to reduce cardiovascular mortality

  2006cites this paper
• Spotlight on Pioglitazone in Type 2 Diabetes Mellitus

  2006cites this paper
• Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer study.

  2005cites this paper
• Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

  2005cites this paper
• Home blood glucose monitoring in Type 2 diabetes

  2005cites this paper
• Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control.

  2005cites this paper
• Clinical networks in diabetes

  2005cites this paper
• Editorial

  2005cites this paper
• Competency‐based education and assessment, the route to competent healthcare professionals

  2005cites this paper
• Dyslipidaemia in Type 2 diabetes: effects of the thiazolidinediones pioglitazone and rosiglitazone

  2005cites this paper
• [Pioglitazone. Review of its metabolic and systemic effects].

  2005cites this paper
• Pioneer Study: PPARγ Activation Results in Overall Improvement of Clinical and Metabolic Markers Associated with Insulin Resistance Independent of Long-term Glucose Control

  2005cites this paper
• Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes.

  2005cites this paper
• Pioglitazona. Revisión de sus efectos metabólicos y sistémicos

  2005cites this paper
• What's new in the journals?

  2005cites this paper
• Current literature in diabetes.

  2005cites this paper
• Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes.

  2005cites this paper
• Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.

  2005cites this paper
• Combination Therapy in Alzheimer’s Disease

  2004cites this paper